PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 28, 2026Cancer Treatment and Research Communications0 citationsOpen Access

Comparative Efficacy of Pegfilgrastim and Filgrastim in Stem Cell Collection for Myeloma

Pegfilgrastim versus Filgrastim for Chemo-Mobilized Stem Cell Collection in Multiple Myeloma: A Retrospective Real-World Study

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYanlin ZhangXQXin-Yi QinCCChun Cao

Discussion

Loading...

Member takes

Overview

Retrospective trial compares pegfilgrastim and filgrastim in stem cell collection, indicating varying efficacy and efficiency.

Key Points

  • Evaluate the efficacy, safety, efficiency, and costs of pegfilgrastim versus filgrastim in multiple myeloma patients.
  • Single-center retrospective study including 102 multiple myeloma patients (PEG: n=49; FIL: n=53)
  • Primary endpoints included CD34⁺ cell yield, mobilization success, duration, and time to engraftment
  • Statistical analyses utilized propensity score matching and overlap weighting
  • Equivalent median CD34⁺ yields for PEG (3.90 × 10⁶/kg) and FIL (4.99 × 10⁶/kg, P=0.096)
  • FIL showed a higher total mononuclear cell count (P<0.001)
  • PEG significantly reduced mobilization duration (10 vs. 15 days, P<0.001) and sessions (P=0.02)

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a17dd123fad632b0f9d9c3ahttps://doi.org/10.1016/j.ctarc.2026.101263
View Full Paper
Ask AI
Bookmark
Share